Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS) Oct 16, 2017 8:00am EDT
Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 Sep 11, 2017 8:00am EDT
Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Aug 22, 2017 4:35pm EDT
Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer Aug 22, 2017 8:00am EDT
Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights Aug 07, 2017 4:05pm EDT
Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference Aug 02, 2017 8:00am EDT
Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) Jul 31, 2017 8:10am EDT
